Talk:5-HT2C receptor agonist
| This is the talk page for discussing improvements to the 5-HT2C receptor agonist article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Copy edit for style? edit
Responding to this note. This article is very technical, but the style seems okay. I've seen much worse.
Would someone care to clarify? Kortoso (talk) 22:22, 28 October 2015 (UTC)
Mechanism Section Technical Flag edit
The Mechanism section of this article could be improved for the general Wikipedia audience. While scientists with some biology background may be able to understand this section, the average reader is likely to struggle. Is it possible to rewrite this section, streamlining to focus on agonist mechanism of action, with a much simpler, minimalist description of only the relevant (to agonist action) receptor/receptor mechanism of action biology? The receptor composition, mechanism of action, etc. details are covered in linked articles. Laatu (talk) 16:10, 9 January 2016 (UTC)
Request for Update edit
Regarding: As of 2012, Vabicaserin is in clinical trials for the treatment of schizophrenia. Does anyone know the outcome of those trials & if so, could you please update this section (with references)? Thank you. Laatu (talk) 16:53, 9 January 2016 (UTC)